MIDAS (Migraine Disability Assessment Score) is a brief self-report questionnaire used clinically to quantify migraine- related disability over the past 3 months. It takes about 90 seconds to complete and produces a single number that helps clinicians make treatment decisions.

It’s one of the most commonly used disability assessments in headache practice — both in research and in real clinics — because it converts subjective “migraine is bad” into something trackable.

The 5 questions

The instrument asks for the number of days in the past 3 months that migraine has affected:

  1. Missed work or school days entirely due to migraine.
  2. Work or school days at reduced productivity (50% or less of normal effectiveness).
  3. Missed household work days entirely.
  4. Reduced productivity household work days (50% or less).
  5. Days missed family, social, or leisure activities because of migraine.

Plus two informational items:

  • A. Number of days in the past 3 months with any headache.
  • B. Average pain severity of headaches on a 0–10 scale.

Total MIDAS score = sum of the 5 numbered questions.

Score interpretation

The published grading bands:

GradeScoreDisability
I0–5Little or none
II6–10Mild
III11–20Moderate
IV21+Severe

Clinical implications:

  • Grade I: usually managed with acute treatment as needed.
  • Grade II: preventive medication consideration starts here if attacks are frequent.
  • Grade III: typically prompts preventive medication discussion.
  • Grade IV: often triggers specialist referral, more aggressive preventive regimens, and disability documentation for work or school accommodations.

Why MIDAS exists

Headache severity is hard to measure in a way that’s both quick and comparable across patients. Pain ratings vary in interpretation; “number of headache days” misses severity; visit- to-visit recall is unreliable.

MIDAS is built around a clinically meaningful endpoint (disability) using anchor points (specific activity days) that are easier to recall accurately than pain levels. It also captures the dimensions of disability that matter clinically — being unable to work or attend school is more informative than just “the pain was bad”.

The validation history (Stewart 1999 and follow-ups) shows good test-retest reliability and predictive value for treatment benefit. It’s stable enough to be a useful trend marker over months and years.

MIDAS vs HIT-6

HIT-6 (Headache Impact Test, 6-item) is the other commonly used disability assessment. Key differences:

FeatureMIDASHIT-6
Recall windowPast 3 monthsPast 4 weeks
Number of items5 + 2 informational6
OutputDay-based score36–78 score
Best forQuarterly tracking, severity gradingVisit-to-visit change

Many practices use both — MIDAS for periodic comprehensive assessment, HIT-6 for tracking treatment response between visits.

Where Hermly fits

Hermly doesn’t currently compute the formal MIDAS questionnaire — the input requires user self-report on activity days that the app doesn’t track natively.

What Hermly’s doctor report does provide:

  • Attack frequency (headache days, migraine days) over the past 3 months.
  • Average pain severity across logged attacks.
  • Distribution of attack durations.

This data lets a clinician quickly estimate MIDAS during a visit — or administer the formal questionnaire with most of the informational items already populated.

Adding the formal MIDAS as an in-app questionnaire (with periodic prompts to complete it) is a reasonable future feature.

What this isn’t

Not a self-diagnosis tool. MIDAS quantifies disability for treatment decisions but doesn’t diagnose migraine. The scoring bands are useful prognostic markers, not absolute treatment triggers — clinical judgment factors in comorbidities, prior treatments, and patient preferences.